Michel Cucherat
LightNews LightNews
Michel Cucherat
@mcucherat.bsky.social
440 followers 230 following 4 posts
Posts Replies Media Videos
Reposted by Michel Cucherat
yalecrrit.bsky.social
We are excited to share a recently published article in Clinical Trials which investigated confirmatory evidence supporting single pivotal trials for new drug approvals. (1/8)
November 3, 2025 at 6:35 PM
Assessing outcomes emerging after conversion to regular approval for cancer drug indications granted accelerated approval, 1992-2021 url: academic.oup.com/jnci/article...
Assessing outcomes emerging after conversion to regular approval for cancer drug indications granted accelerated approval, 1992-2021
AbstractBackground. The FDA’s accelerated approval pathway expedites cancer drug approvals based on surrogate measures, while clinical benefit is assessed
academic.oup.com
October 30, 2025 at 4:10 PM
Reposted by Michel Cucherat
astropierre.com
La dernière étude d'OpenAI prouve mathématiquement que les grands modèles linguistiques produiront toujours des résultats plausibles mais faux (hallucinations), même avec des données parfaites, à cause de la nature statistiques des algorithmes en jeu.

www.computerworld.com/article/4059...
OpenAI admits AI hallucinations are mathematically inevitable, not just engineering flaws
In a landmark study, OpenAI researchers reveal that large language models will always produce plausible but false outputs, even with perfect data, due to fundamental statistical and computational limi...
www.computerworld.com
September 21, 2025 at 9:20 AM
Reposted by Michel Cucherat
robinbougie.bsky.social
Someone was trying to take a portrait of their two fave Chickens, and this happened.
September 20, 2025 at 6:59 AM
Reposted by Michel Cucherat
odedrechavi.bsky.social
CRISPR is amazing
September 21, 2025 at 12:56 PM
Reposted by Michel Cucherat
fzores.bsky.social
C'est joli les scores, ça fait des publications, ca donne l'air malin, ca dit que les patients tres malades sont très malades et ont plus de risque de mourir, c'est poussé par des KOL

Et quand on les évalue correctement...
September 8, 2025 at 2:44 PM
Reposted by Michel Cucherat
jdwilko.bsky.social
www.medrxiv.org/content/10.1...

INSPECT-SR: A tool for assessing trustworthiness of randomised controlled trials.
INSPECT-SR: a tool for assessing trustworthiness of randomised controlled trials
The integrity of evidence synthesis is threatened by problematic randomised controlled trials (RCTs). These are RCTs where there are serious concerns about the trustworthiness of the data or findings....
www.medrxiv.org
September 5, 2025 at 6:11 PM
Reposted by Michel Cucherat
lepoint.fr
Alzheimer : polémique autour du Leqembi, un médicament à quelques milliards d’euros

Par @olivierhertel.bsky.social
Alzheimer : polémique autour du Leqembi, un médicament à quelques milliards d’euros
l.lepoint.fr
July 20, 2025 at 9:22 AM
Reposted by Michel Cucherat
statsepi.bsky.social
If you are analyzing clinical data, you almost certainty don't need a multivariable model unless you are building a prognostic model or asking causal questions. Statistics shouldn't be a performance.
July 4, 2025 at 1:43 PM
Reposted by Michel Cucherat
statsepi.bsky.social
Relevant:

(from statsepi.substack.com/p/sorry-what... ICYMI)
People often say their goal is to identify “risk factors”. But what does that mean? Some people use the term to indicate potential causes of outcomes. Then just say cause. Others use it to identify predictors of outcomes. Then just say predict. And, sadly, too many others use it as shorthand for factors that are “statistically associated” with outcomes. In this case, say nothing at all, since this “goal” has no clinical utility whatsoever (beyond what it might suggest about causation or prediction). So once you have framed your research question as description, prediction, causation or measurement, there is no longer a need to talk about risk factors. It's basically just a catch-all phrase to cover up muddy thinking.
July 4, 2025 at 2:14 PM
Reposted by Michel Cucherat
statsepi.bsky.social
I'm not saying you can't generate a hypothesis from data.

I'm just saying that generating a hypothesis from the entirety of human knowledge that preceded your data is a much safer bet.
July 4, 2025 at 2:16 PM
Reposted by Michel Cucherat
cressumr1153.bsky.social
Read our paper in JAMA Internal Med with a great editorial. Wonderful collaboration with @gcabanac.cpesr.fr

Retracted papers are included in meta-analyses published in HIF journal. Inclusion of the retracted studies changed
effect estimates.
jamanetwork.com/journals/jam...
Inclusion of Retracted Studies in Systematic Reviews and Meta-Analyses of Interventions
This systematic review and meta-analysis identifies reports of systematic reviews that included retracted studies in their meta-analyses, and assesses the impact of these retracted studies on the resu...
jamanetwork.com
April 17, 2025 at 2:16 PM
Reposted by Michel Cucherat
mendelrandom.bsky.social
Triangulation of evidence in medical research explained, in work led by Sirena Gutierrez and @mariaglymour.bsky.social Will do a thread when I get a moment
link.springer.com/article/10.1...
Evidence triangulation in health research - European Journal of Epidemiology
For many important questions about influences on clinical and public health outcomes, no single study can provide a decisive answer. The perfect study—a large, diverse, well-conducted trial randomizin...
link.springer.com
March 28, 2025 at 8:30 PM
Reposted by Michel Cucherat
floriannaudet.bsky.social
Provenance and funding of extremely cited biomedical papers published in 2003- 2004, 2013-2014 and 2023-2024
www.medrxiv.org
March 9, 2025 at 7:10 AM
Reposted by Michel Cucherat
jclinepi.bsky.social
Definitions of Validity Terms for Use in Discussions of Randomized Controlled Trials - Journal of Clinical Epidemiology www.jclinepi.com/article/S089...
Definitions of Validity Terms for Use in Discussions of Randomized Controlled Trials
We review existing definitions and usages of validity terms and propose a single definition for each term for use in communicating inferences from Randomized Controlled trials (RCTs).
www.jclinepi.com
March 9, 2025 at 8:27 PM
Reposted by Michel Cucherat
floriannaudet.bsky.social
Analysis of indications for selectively missing results in comparative registry-based studies in medicine: a meta-research study
Analysis of indications for selectively missing results in comparative registry-based studies in medicine: a meta-research study - Research Integrity and Peer Review
Background We assess if there are indications that results of registry-based studies comparing the effectiveness of interventions might be selectively missing depending on the statistical significance...
researchintegrityjournal.biomedcentral.com
March 8, 2025 at 6:03 AM
Reposted by Michel Cucherat
jama.com
Viewpoint: Proposals to lower or eliminate the @fda.gov's preapproval effectiveness requirements for drugs are unnecessary and dangerous, as they undermine patient safety and public health. https://ja.ma/4brnk39
Image shows website.
March 6, 2025 at 4:35 PM
Reposted by Michel Cucherat
tctmd.bsky.social
ICYMI: ‘Arbitrary’ Hodgepodge of Composite Endpoints Used Across ASCVD Trials
‘Arbitrary’ Hodgepodge of Composite Endpoints Used Across ASCVD Trials
‘Arbitrary’ Hodgepodge of Composite Endpoints Used Across ASCVD Trials [email protected] Thu, 02/20/2025 - 16:31 Michael O'Riordan A minority of studies used the standard three-point MACE endpoint, and many tweaked their endpoints along the…
www.tctmd.com
February 23, 2025 at 9:40 PM
Reposted by Michel Cucherat
maartenvsmeden.bsky.social
This is sad...
eikofried.bsky.social Eiko Fried @eikofried.bsky.social · Feb 20
Wrote Scientific Reports February 8 2024 that a newly published meta-analysis on mindfulness & brain morphology excluded all null-findings and therefore ... by definition found a relationship.

Still no proper response from the journal (other then many "we'll look into it"). It's been a year now.
February 22, 2025 at 9:33 AM
Reposted by Michel Cucherat
stats-tobby.bsky.social
doi.org/10.1002/sim....

Our paper "A Comparison of Statistical Methods for Time-To-Event Analyses in Randomized Controlled Trials Under Non-Proportional Hazards" got published today 🎉

We describe commonly used methods, and compare their performance in a simulation study across different scenarios.
A Comparison of Statistical Methods for Time‐To‐Event Analyses in Randomized Controlled Trials Under Non‐Proportional Hazards
While well-established methods for time-to-event data are available when the proportional hazards assumption holds, there is no consensus on the best inferential approach under non-proportional hazar...
doi.org
February 20, 2025 at 2:00 PM
Reposted by Michel Cucherat
jama.com
A more than doubled rate of nirmatrelvir-ritonavir prescriptions was not associated with reductions in hospitalizations or mortality among highly vaccinated older adults in Canada.

ja.ma/3ENOh4U

#MedSky
Figure. Regression Discontinuities of Nirmatrelvir-Ritonavir Prescription, COVID-19–Related Hospitalization, and All-Cause Hospitalization and Death Rates per 100 000 Older Adults, April 1–November 30, 2022, Ontario
February 20, 2025 at 9:04 PM
Reposted by Michel Cucherat
jama.com
"We cannot think that our AI systems will not be biased. There will always be a risk of bias."

María Villalobos-Quesada, a researcher at Leiden University Medical Centre, discusses the need for transparent and consistent reporting of quality for #AI tools with JAMA+ AI.

#MedSky
Evidence Lacking for Many AI Tools Used in Primary Care
This Medical News article is an interview with study author María Villalobos-Quesada, PhD, a researcher at the National eHealth Living Lab at the Leiden University Medical Centre in the Netherlands.
jamanetwork.com
February 19, 2025 at 6:22 PM
Reposted by Michel Cucherat
jclinepi.bsky.social
Author’s reply : “The importance of properly specifying your target trial emulation: commentary on Mésidor et al.” - Journal of Clinical Epidemiology www.jclinepi.com/article/S089...
Author’s reply : “The importance of properly specifying your target trial emulation: commentary on Mésidor et al.”
Not applicable.
www.jclinepi.com
February 16, 2025 at 7:13 PM
Reposted by Michel Cucherat
jeffreybrainard.bsky.social
Many #researchintegrity sleuths are volunteers with little financial support for their often-daunting work to uncover #scientificfraud. One of the most prominent, Elisabeth Bik, has now provided money to change that. @elisabethbik.bsky.social @science.org www.science.org/content/arti...
Renowned scientific integrity investigator endows fund to support fellow sleuths
Microbiologist Elisabeth Bik donates $200,000 to support training, travel
www.science.org
February 13, 2025 at 5:08 PM
Reposted by Michel Cucherat
richarddriley.bsky.social
**NEW BMJ PAPER**

"Uncertainty of risk estimates from clinical prediction models: rationale, challenges, and approaches"

- most models provide just a risk estimate
- we argue for presenting associated uncertainty too
- includes pros, cons, PPIE & methods

Hope helpful!
www.bmj.com/content/388/...
Uncertainty of risk estimates from clinical prediction models: rationale, challenges, and approaches
Clinical prediction models estimate an individual’s risk (probability) of a health related outcome to help guide patient counselling and clinical decision making. Most models provide a single point es...
www.bmj.com
February 13, 2025 at 11:13 AM